Arianna Ghirardi

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial

Tiziano Barbui, Alessandro M. Vannucchi, Valerio De Stefano et al. · The Lancet Haematology · 2021 · 125 citations · Full text

Polycythaemia Vera, Hematology, Low-pv Study +2

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Tiziano Barbui, Arianna Ghirardi, Arianna Masciulli et al. · Leukemia · 2019 · 87 citations · Full text

Hematological Malignancy, Medicine, Pathology +6

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui, Alessandro M. Vannucchi, Alberto Álvarez‐Larrán et al. · Leukemia · 2021 · 80 citations · Full text

A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study

Tiziano Barbui, Alessandro M. Vannucchi, Guido Finazzi et al. · American Journal of Hematology · 2017 · 79 citations · Full text

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases

Valerio De Stefano, Elena Rossi, Alessandra Carobbio et al. · Blood Cancer Journal · 2018 · 72 citations · Full text